NCT03160079 - Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 4, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

B-Cell Acute Lymphoblastic Leukemia, Adult

Interventions

DRUG

blinatumomab

"Cycle 1 Blinatumomab Day 1-7 Continuous IV infusion for 28 days (9 mcg/day) Blinatumomab Day 8-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle 2-5 Blinatumomab Day 1-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle length 42 days"

DRUG

pembrolizumab

"Cycle 1 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)~Cycle 2-5 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)"

Trial Locations (4)

92093

UC San Diego Moores Cancer Center, La Jolla

92868

UC Irvine Health Chao Family Comprehensive Cancer Center, Orange

93611

UCSF Fresno Community Cancer Institute, Clovis

94143

UCSF Comprehensive Cancer Center, San Francisco